title: Myeloproliferative neoplasms and thrombosis.
abstract: Major causes of morbidity and mortality in myeloproliferative neoplasms are represented by arterial and venous complications, progression to myelofibrosis, and transformation to acute leukemia. The pathogenesis of thrombosis results from a complex interplay of clinical and disease-related factors. Abnormalities of blood cells arising from the clonal proliferation of hematopoietic stem cells involve not only quantitative changes but also qualitative modifications that characterize the switch of these cells from a resting to a procoagulant phenotype. According to age and previous thrombosis, patients are classified in a "high risk" or "low risk". Novel disease-related determinants such as leukocytosis and JAK2V617F mutational status and/or mutational burden are now under active investigation. In low-risk polycythemia vera patients, only phlebotomy and primary antithrombotic prophylaxis with aspirin is recommended, while in high-risk patients cytotoxic therapy is considered. Whether novel drugs targeting the constitutively active JAK2/STAT pathway will improve the management of thrombosis is a challenge for future studies.
authors.affiliation: Research Foundation.
authors.forename: Tiziano
authors.initials: T
authors.lastname: Barbui
authors.forename: Guido
authors.initials: G
authors.lastname: Finazzi
authors.forename: Anna
authors.initials: A
authors.lastname: Falanga
mesh_terms: D006801:Humans; D009196:Myeloproliferative Disorders / Q000150:complications*; D012307:Risk Factors; D013927:Thrombosis / Q000209:etiology*